Like my comment thanks_老虎社区_美港股上老虎

Abu888
2021-09-16

Like my comment thanks

3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>

Here are three healthcare stocks as nominees for a quick double in 2021.

3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":885606416,"tweetId":"885606416","gmtCreate":1631781443235,"gmtModify":1631883968966,"author":{"id":3581658741892979,"idStr":"3581658741892979","authorId":3581658741892979,"authorIdStr":"3581658741892979","name":"Abu888","avatar":"https://static.tigerbbs.com/39dfd9ec19b4b4e5c99cbc270b33e932","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like my comment thanks</body></html>","htmlText":"<html><head></head><body>Like my comment thanks</body></html>","text":"Like my comment thanks","highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/885606416","repostId":1195990706,"repostType":4,"repost":{"id":"1195990706","kind":"news","pubTimestamp":1631781148,"share":"https://www.laohu8.com/m/news/1195990706?lang=zh_CN&edition=full","pubTime":"2021-09-16 16:32","market":"us","language":"en","title":"3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195990706","media":"Motley Fool","summary":"Here are three healthcare stocks as nominees for a quick double in 2021.","content":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.<blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote> Read more to find out why we think&nbsp;Novavax(NASDAQ:NVAX),&nbsp;Sorrento Therapeutics(NASDAQ:SRNE), and&nbsp;InMode(NASDAQ:INMD)will close out 2021 with a bang.<blockquote>阅读更多内容，了解我们为什么认为Novavax（纳斯达克：NVAX），索伦托治疗公司（纳斯达克：SRNE），以及InMode（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote> <img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Multiple catalysts will make Novavax shares jump in 2021<blockquote>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</blockquote> Taylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.<blockquote>泰勒·卡迈克尔（Novavax）：Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote> Right now,Moderna&nbsp;enjoys a $169 billion market cap, and&nbsp;BioNTech&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.<blockquote>现在，现代市值为1690亿美元，BioNTech估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.<blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.<blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.<blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和作为世界上大多数未接种疫苗的人的初始疫苗受到欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote> 2. Sorrento Therapeutics: Don't sleep on this name<blockquote>2.Sorrento Therapeutics：别睡在这个名字上</blockquote> George Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.<blockquote>George Budwell（Sorrento Therapeutics）：由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.<blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.<blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote> 3. InMode stock will spike as the world reopens<blockquote>3.随着世界重新开放，InMode股票将飙升</blockquote> Patrick Bafuma&nbsp;(InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.<blockquote>帕特里克·巴富马 （在模式中）：随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.<blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.<blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"<blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.<blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.<blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-16 16:32\n\n</h4>\n</header>\n<article>\nAnything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.<blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote> Read more to find out why we think&nbsp;Novavax(NASDAQ:NVAX),&nbsp;Sorrento Therapeutics(NASDAQ:SRNE), and&nbsp;InMode(NASDAQ:INMD)will close out 2021 with a bang.<blockquote>阅读更多内容，了解我们为什么认为Novavax（纳斯达克：NVAX），索伦托治疗公司（纳斯达克：SRNE），以及InMode（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote> <img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Multiple catalysts will make Novavax shares jump in 2021<blockquote>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</blockquote> Taylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.<blockquote>泰勒·卡迈克尔（Novavax）：Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote> Right now,Moderna&nbsp;enjoys a $169 billion market cap, and&nbsp;BioNTech&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.<blockquote>现在，现代市值为1690亿美元，BioNTech估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.<blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.<blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.<blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和作为世界上大多数未接种疫苗的人的初始疫苗受到欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote> 2. Sorrento Therapeutics: Don't sleep on this name<blockquote>2.Sorrento Therapeutics：别睡在这个名字上</blockquote> George Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.<blockquote>George Budwell（Sorrento Therapeutics）：由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.<blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.<blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote> 3. InMode stock will spike as the world reopens<blockquote>3.随着世界重新开放，InMode股票将飙升</blockquote> Patrick Bafuma&nbsp;(InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.<blockquote>帕特里克·巴富马 （在模式中）：随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.<blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.<blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"<blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.<blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.<blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","SRNE":"索伦托医疗","INMD":"InMode Ltd."},"source_url":"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195990706","content_text":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.\nRead more to find out why we think Novavax(NASDAQ:NVAX), Sorrento Therapeutics(NASDAQ:SRNE), and InMode(NASDAQ:INMD)will close out 2021 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\n1. Multiple catalysts will make Novavax shares jump in 2021\nTaylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.\nRight now,Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.\nThe majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.\nThe U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.\nI'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.\n2. Sorrento Therapeutics: Don't sleep on this name\nGeorge Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.\nThe core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.\nIt is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.\n3. InMode stock will spike as the world reopens\nPatrick Bafuma (InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.\nUsing a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.\nAnd this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.\nAs the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"\nTheodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.\nWith many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.","news_type":1,"symbols_score_info":{"INMD":0.9,"NVAX":0.9,"SRNE":0.9}},"isVote":1,"tweetType":1,"viewCount":1407,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>

评论（2）

热议股票